Eli Lilly and Company is a global pharmaceutical corporation that specializes in the discovery, development, manufacturing, and distribution of medicines. Its portfolio spans various therapeutic areas, including neuroscience, cardiometabolic, cancer, and immunology. Notable products include Verzenio for cancer, Mounjaro and Jardiance for cardiometabolic conditions, and Taltz for immunology. The company operates through owned or leased facilities in over 25 countries, selling its products in approximately 135 countries worldwide. Additionally, Eli Lilly and Company Foundation, established in 1968, supports initiatives aimed at improving patient outcomes, enhancing quality of life, and promoting education, particularly in underserved communities.
Group Vice President - Molecule Discovery and Director, Lilly Institutes of Genetic Medicine
Anat Ashkenazi
CFO
Gordon Brooks
Group Vice President - Controller and Corporate Strategy
Lotus Mallbris Ph.D
Vice President of Development and Immunology
Teresa Millan
Corporate Affairs Director
Jacob Van Naarden
President
Diogo Rau
Executive Vice President and Chief Information and Digital Officer
Melissa Seymour
Executive VP of Global Quality
Past deals in Belgium
Augustine Therapeutics
Series A in 2025
Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.
Augustine Therapeutics
Series A in 2024
Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.